Freedom of information questions (time parameters 1st January 2017 to date:
1. What is the policy of the Maidstone and Tunbridge Wells Trust in terms of supporting NHS patients who have had drug and medication recommended to them which is not funded by the NHS, and who have privately paid for the drugs. The NHS support amounting to Consultation and/or/drug administration and/or blood tests and/or aftercare by NHS staff.
2. Within the Oncology Department, how many patients who have privately paid for a drug which is not funded by the NHS are receiving support as described above by the NHS and its staff.
3. Within the Oncology Department, how many NHS second line patients who have privately paid for the drug Palbociclib, as it is not funded by the NHS are receiving support and care as outlined above.
4. How many other Departments adopt this policy of NHS support for NHS patients who have had to privately pay for their medication, as it is not funded by the NHS.
5. Does the Maidstone and Tunbridge Wells NHS Trust support any NHS patients who have had to pay privately for the drug Rituximab as it is not NHS funded?
6. In the event of a positive answer to 5. above, which department provides the support and for the treatment of which disease?

Download response Self-funding drug and medications 220818